Adverse event management strategies: Optimizing treatment with regorafenib in patients with metastatic colorectal cancer

Clinical Journal of Oncology Nursing

Volumn 18, Issue 2, 2014, Pages

  Mitchell, Jessica ^a   Khoukaz, Taline ^b   McNeal, Deborah ^c   Brent, Lori ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Charleston Hematology Oncology Associates   (United States)

^d Jackson Oncology Associates   (United States)

Author keywords

Biotherapy targeted therapy; Gastrointestinal malignancies

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE; REGORAFENIB;

CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; DIARRHEA; DRUG EFFECTS; FATIGUE; HUMAN; HYPERTENSION; LIVER; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; STOMATITIS;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DIARRHEA; FATIGUE; HUMANS; HYPERTENSION; LIVER; NEOPLASM METASTASIS; PHENYLUREA COMPOUNDS; PYRIDINES; STOMATITIS;

EID: 84897080344     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/14.CJON.E19-E25     Document Type: Article

References (15)

1. Albert, K. (2005). Hypertension in the oncology setting. Clinical Journal of Oncology Nursing, 9, 677-680. doi:10.1188/05.CJON.677-680
2. Bayer HealthCare. (2012). Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy [Data on file]. Retrieved from: http://clinicaltrial.gov/show/NCT01103323
3. Bayer HealthCare. (2013). Stivarga® (regorafenib) [Prescribing information]. Retrieved from http://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf
4. Benson, A.B., Ajani, J.A., Catalano, R.B., Engelking, C., Kornblau, S.M., Martenson, J.A., Wadler, S. (2004). Recommended guidelines for the treatment of cancer treatment-induced diarrhea. Journal of Clinical Oncology, 22, 2918-2926. doi:10.1200/JCO.2004.04.132
5. Bhattacharya, D., Easthall, C., Willoughby, K.A., Small, M., & Watson, S. (2012). Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors. Journal of Oncology Pharmacy Practice, 18, 333-342. doi:10.1177/1078155211436022
6. Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Laurent, D. (2013a). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381, 303-312. doi:10.1016/S0140-6736(12) 61900-X
7. Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Laurent, D. (2013b). Time course of regorafenib-associated adverse events in the phase III CORRECT study [Abstract 467]. Retrieved from http://meetinglibrary.asco.org/content/106063-133
8. Lacouture, M.E., Wu, S., Robert, C., Atkins, M.B., Kong, H.H., Guitart, J., Dutcher, J.P. (2008). Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist, 13, 1001-1011. doi:10.1634/theoncologist.2008-0131
9. Peterson, D.E., Bensadoun, R.J., & Roila, F. (2011). Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Annals of Oncology, 22(Suppl. 6), vi78-vi84. doi:10.1093/annonc/mdr391
10. Peterson, D.E., Keefe, D.M., & Sonis, S.T. (2012). New frontiers in mucositis. Retrieved from http://meetinglibrary.asco.org/sites/meetinglibrary.asco.org/files/Educational%20Book/PDF%20Files/2012/zds00112000545.pdf
11. Ruddy, K., Mayer, E., & Partridge, A. (2009). Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clincians, 59, 56-66.
12. Schwandt, A., Wood, L.S., Rini, B., & Dreicer, R. (2009). Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. OncoTargets and Therapy, 2, 51-61.
13. Stein, A., Voigt, W., & Jordan, K. (2010). Chemotherapy-induced diarrhea: Pathophysiology, frequency, and guideline-based management. Therapeutic Advances in Medical Oncology, 2, 51-63. doi:10.1177/1758834009355164
14. Wilhelm, S.M., Dumas, J., Adnane, L., Lynch, M., Carter, C.A., Schutz, G., Zopf, D. (2011). Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer, 129, 245-255. doi:10.1002/ijc.25864
15. Wood, L., Lemont, H., Jatoi, A., Lacouture, M.E., Robert, C., Keating, K., & Anderson, R. (2010). Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncology, 7, 23-29. doi:10.1016/S1548-5315(11)70385-0